Medical Risk Classification For Severe COVID-19 Based On Chronic Medical Conditions: A Comparative Analysis

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Сен. 6, 2024

Abstract Background The European Centre for Disease Prevention and Control (ECDC) provides listings of medical conditions conferring high- or moderate-risk severe COVID-19. In addition, individual countries developed their own risk classifications COVID-19 to select individuals recommended annual vaccination. We assessed the discordance between respective national in assigning children adults groups developing populations Netherlands Norway. Methods This multi-country, healthcare data-linkage study covered 17.4 million inhabitants 5.6 Norway by 1 January 2020. Medical were defined based on ICD-10 hospital discharge codes Dutch classifications, ICPC-2 primary care Norwegian classification. Subjects classified as high-, moderate-, low-risk. Discordance was calculated proportion population with a different status compared Findings overall classification 12.0% 13.8% population. assigns more high-risk (9.0% 9.2% populations, respectively) than (1.5% 3.0%, respectively). National define (11.3% 12.7%, (1.0% 1.3%, Classification discordances most frequently involved subjects cardiovascular disease, lung diabetes mellitus. Interpretation defines substantially larger percentage classifications. may have implications post-pandemic vaccination programs. Further research should assess what extent responsible determine Funding ZonMw, EU, FCT, Research Council’s Emergency Call, iAPOGEE. context Evidence before this searched PubMed English-language articles published from 2020 July 2024, using search terms ((((“COVID-19“[Title] OR “SARS-CoV-2“[Title]) AND (“sever*“[Title] “hospital*“[Title] “death“[Title] “decease*“[Title]) (“chronic condition*“[Title/Abstract] “comorbidit*“[Title/Abstract]) (“guideline“[Title] “classification“[Title] “system“[Title]) 2020/01/01:2024/07/01[Date - Create]) NOT “clinical trial“[Publication Type]) “case reports“[Publication Type]). identified 64 studies, but none them impact across Added value To best our knowledge, is first that registries. demonstrated important discrepancies schemes classifying both countries. chronic neurological disorders, mellitus, cancer, hypertension. Implications all available evidence Our comparative analysis suggests choice consequences public health interventions such campaigns. variability assignment underscores absence an international uniform approach. More needed which each condition impacts severity period, facilitating refinement supporting targeted interventions.

Язык: Английский

---

Influence of Bronchopulmonary Diseases on the Course and Outcome of COVID-19: a Literature Review

Juvenis scientia, Год журнала: 2024, Номер 10(4), С. 19 - 28

Опубликована: Авг. 30, 2024

The SARS-CoV‑2 coronavirus has become a major global health concern. Infection with caused millions of deaths worldwide, and the case fatality rate been found to be largely related pre-existing clinical conditions. main manifestation COVID‑19 is presence respiratory symptoms. Severe complications are most often observed in people significant medical histories. virus primarily attacks system, causing pneumonia acute distress syndrome, which can lead severe systemic inflammation, multiple organ dysfunction, death, especially patients comorbidities. A number meta-analyses strongly suggest that comorbid diseases, including chronic obstructive pulmonary disease interstitial lung factors development forms COVID‑19, worsening patient outcomes survival rates. Studies have shown an association between adverse expression level angiotensin-­converting enzyme 2 (ACE2) these patients. Regarding other system pathologies, such as bronchial asthma cystic fibrosis, it known unfavorable factor long-term immunosuppressive pharmacotherapy preceding infection. In this article, we highlight comorbidities better understand pathogenesis COVID‑19.

Язык: Английский

---

New Evidence for SARS-CoV-2 Vaccine Boosting in Patients With Chronic Lung Diseases

CHEST Journal, Год журнала: 2024, Номер 166(4), С. 655 - 656

Опубликована: Окт. 1, 2024

Язык: Английский

---

Response

CHEST Journal, Год журнала: 2024, Номер 166(5), С. e167 - e168

Опубликована: Ноя. 1, 2024

---

Delta and Omicron SARS-CoV-2 Outcomes in Vaccinated Individuals With Chronic Lung Disease

CHEST Journal, Год журнала: 2024, Номер 166(5), С. e167 - e167

Опубликована: Ноя. 1, 2024

Язык: Английский

---